Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation†
Article first published online: 27 MAY 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 48, Issue 3, pages 732–740, September 2008
How to Cite
Kato, T., Choi, Y., Elmowalid, G., Sapp, R. K., Barth, H., Furusaka, A., Mishiro, S., Wakita, T., Krawczynski, K. and Liang, T. J. (2008), Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology, 48: 732–740. doi: 10.1002/hep.22422
Potential conflict of interest: Nothing to report.
- Issue published online: 27 AUG 2008
- Article first published online: 27 MAY 2008
- Accepted manuscript online: 27 MAY 2008 12:00AM EST
- Manuscript Accepted: 7 MAY 2008
- Manuscript Received: 4 FEB 2008
- Scientific Research from the Japan Society for the Promotion of Science
- Ministry of Health, Labor, and Welfare of Japan
- Research on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation
- Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases
- Division of Viral Hepatitis, Center for Disease Control and Prevention
The identification of the hepatitis C virus (HCV) strain JFH-1 enabled the successful development of infectious cell culture systems. Although this strain replicates efficiently and produces infectious virus in cell culture, the replication capacity and pathogenesis in vivo are still undefined. To assess the in vivo phenotype of the JFH-1 virus, cell culture–generated JFH-1 virus (JFH-1cc) and patient serum from which JFH-1 was isolated were inoculated into chimpanzees. Both animals became HCV RNA-positive 3 days after inoculation but showed low-level viremia and no evidence of hepatitis. HCV viremia persisted 8 and 34 weeks in JFH-1cc and patient serum–infected chimpanzees, respectively. Immunological analysis revealed that HCV-specific immune responses were similarly induced in both animals. Sequencing of HCV at various times of infection indicated more substitutions in the patient serum–inoculated chimpanzee, and the higher level of sequence variations seemed to be associated with a prolonged infection in this animal. A common mutation G838R in the NS2 region emerged early in both chimpanzees. This mutation enhances viral assembly, leading to an increase in viral production in transfected or infected cells. Conclusion: Our study shows that the HCV JFH-1 strain causes attenuated infection and low pathogenicity in chimpanzees and is capable of adapting in vivo with a unique mutation conferring an enhanced replicative phenotype. (HEPATOLOGY 2008.)
Hepatitis C virus (HCV) infects approximately 170 million people worldwide and is a major causative agent of chronic liver diseases including cirrhosis and hepatocellular carcinoma.1, 2 However, the underlying biological mechanisms of pathogenesis and persistence are still not well understood. No vaccine protecting against HCV infection is currently available.3 Therapy for HCV-related chronic hepatitis remains problematic, with limited efficacy, high cost, and substantial adverse effects.1, 4, 5 Understanding the biology of this virus and the development of new therapies has been hampered by a lack of appropriate model systems for replication and infection of this virus.
Recent progress with a unique HCV genotype 2a strain, JFH-1, isolated from a case of fulminant hepatitis in Japan, has led to the development of a robust HCV infectious cell culture system.6–9 This JFH-1 strain can replicate efficiently, produce the infectious viral particles, and show robust infection in vitro. However, in our previous report, the inoculation of cell culture–generated JFH-1 virus (JFH-1cc) induced only transient and attenuated infection in a chimpanzee.8 The observed low virulence of this strain in vivo was unexpected but consistent, with an inverse relationship between in vivo and in vitro properties of cell culture adaptive mutations in the HCV replicon system.10
In this study, we performed an extensive analysis of the in vivo replication and pathogenicity of the JFH-1 strain by inoculating chimpanzees with JFH-1cc and patient serum from which the JFH-1 strain was isolated. Furthermore, we analyzed viral sequences during the infection to identify mutations that might represent in vivo adaptive mutations with unique phenotypes.
Materials and Methods
The production of JFH-1cc has been reported previously.12 Briefly, the full-length JFH-1 RNA was synthesized by in vitro transcription with linearized pJFH-1 plasmid and MEGAscript kit (Ambion, Austin, TX).8 Ten micrograms full-length JFH-1 RNA was transfected into 3.0 × 106 Huh7 cells by electroporation, and the culture medium with JFH-1cc was harvested 5 days after transfection. The culture medium was passed through a 0.45-μm filter unit. The case of fulminant hepatitis C from which the JFH-1 strain was isolated has been reported previously.6 An aliquot of acute-phase serum (point A as indicated by Kato et al.6) was used in this study. To determine the HCV RNA titers in these inocula, total RNA was extracted from 140 μL of these samples by QIAamp Viral RNA Kit (QIAGEN, Valencia, CA), and copy numbers of HCV RNA were determined by real-time quantitative reverse transcription polymerase chain reaction (RT-PCR), as described previously.13
Infection Study in Chimpanzees.
Housing, maintenance, and care of the chimpanzees used in this study conformed to the requirement for the humane use of animals in scientific research as defined by the Institutional Animal Care and Use Committee of the Centers for Disease Control and Prevention. Chimpanzee 10273 (CH10273, female, age 5, 20 kg) was inoculated intravenously with 100 μL serum (9.6 × 106 copies) from the fulminant hepatitis patient mixed with 400 μL Dulbecco's modified Eagle's medium culture medium. Chimpanzee 10274 (CH10274, female, age 5, 22 kg) was inoculated intravenously with 500 μL Dulbecco's modified Eagle's medium culture medium containing JFH-1cc (1.4 × 107 copies). Serum and liver biopsy samples of these animals were obtained at baseline and weekly after inoculation.
Measurement of HCV RNA, anti-HCV, and Alanine Aminotransferase.
HCV RNA in chimpanzees was quantitatively measured by nested RT-PCR with a sensitivity of detection of approximately 50 IU/mL (COBAS Amplicor; Roche Molecular Systems, Pleasanton, CA) and was quantified using Amplicor Monitor (Roche Molecular Systems). Serum samples were tested for anti-HCV (ORTHO version 3.0 enzyme-linked immunosorbent assay test system, Ortho-Clinical Diagnostics, Raritan, NJ). Serum alanine aminotransferase (ALT) values in chimpanzee's sera were established using a commercially available assay kit in accordance with the manufacturer's instructions (Drew Scientific, Dallas, TX). Cutoff values representing 95% confidence limit for the upper level of normal ALT activity were calculated individually for each chimpanzee using 10 pre-inoculation enzyme values obtained over a period of 4 to 6 weeks, and were 73 U/L in CH10274 and 76 U/L in CH10273.
The total RNA was extracted from 280 μL chimpanzee sera collected at appropriate time points by the use of QIAamp viral RNA kit, and complementary DNA was synthesized by use of Superscript III (Invitrogen, Carlsbad, CA). The complementary DNAs were subsequently amplified with TaKaRa LA Taq DNA polymerase (Takara Mirus Bio, Madison, WI). Five separate fragments were amplified by nested PCR covering the entire open reading frame and a part of the 5′UTR of the JFH-1 strain as follows; nt 128-1829, nt 1763-4381, nt 4278-6316, nt 6172–7904, and nt 7670-9222. The sequence of each amplified fragment was determined directly. The fragment encompassing hypervariable region 1 (HVR-1) (nt 128-1829) was cloned into the pGEM-T easy vector (Promega, Madison, WI) and 10 clones from each time point were sequenced.
T-Cell Proliferation and Interferon-γ Enzyme-Linked Immunosorbent Spot Assays.
The cryopreserved peripheral blood mononuclear cells (PBMCs) were used for immunological analysis. Standard T-cell proliferation assay was performed as described previously.14 Cells were stimulated with recombinant HCV genotype 2a core or NS5a protein (Fitzgerald Industries International, Concord, MA) and pulsed with 3H-thymidine (GE Healthcare BioSciences, Piscataway, NJ). T-cell stimulation was expressed as a stimulation index that was calculated as the ratio of average counts per minute (CPM) of antigen-stimulated proliferation over average CPM of the medium background. A sample was considered positive when the average stimulation index was greater than 5. The numbers of antigen-specific interferon gamma (IFN-γ)–producing cells were analyzed by enzyme-linked immunosorbent spot (ELISpot) assay. PBMCs were stimulated with recombinant protein antigens (HCV core and NS5a proteins) and HCV overlapping peptide pools (15mers overlapped by 10 amino acids) from core (38 peptides, amino acids 1-195) and NS3 (56 peptides, amino acids 1031-315)(Mimotopes, Raleigh, NC). The NS3 overlapping peptide pools were divided into two sets. The number of spots was counted by using a computer-assisted AID ELISpot Reader System and AID software version 3.5 (Autoimmune Diagnostika GmbH, Strassberg, Germany). Antigen-specific spot-forming unit (SFU) was calculated by subtracting the average of background values (four wells without antigen, typically fewer than 10 spots) from that of the antigen-stimulated sample. The sample was considered positive when the background-corrected SFU was greater than 10 and twice or more the mean SFU of the preinfection samples in the same animal.
To specifically evaluate the T-cell response against the NS2 region containing the G838R mutation, two peptides of 18 amino acids (NS2-G: ITLFTLTPGYKTLLGQCL and NS2-R: ITLFTLTPRYKTLLGQCL) were synthesized (Sigma-Genosys, The Woodlands, TX). PBMCs from both chimpanzees were stimulated with the wild-type (WT) and mutant peptides (2 μg/mL) and analyzed for IFN-γ production by IFN-γ ELISpot assays as described.
Production of JFH-1 G838R Mutant Virus.
The full genome JFH-1 construct with G838R mutation in the NS2 region was generated by site-directed mutagenesis. The replication-deficient clone of JFH1 generated by introducing a point mutation into the GDD motif of the NS5B to abolish the RNA-dependent RNA polymerase activity was used as a negative control (JFH-1 GND).8
Quantification of HCV RNA and HCV Core Antigen.
To determine the amount of HCV, total RNA was extracted with QIAamp Viral RNA Kit from 140 μL culture medium, or with RNeasy mini kit (QIAGEN, Valencia, CA) from cell pellet. Copy numbers of HCV RNA were determined by real-time quantitative RT-PCR as described. HCV core antigen (Ag) in culture supernatant was quantified by highly sensitive enzyme immunoassay (Ortho HCV core antigen ELISA Kit, Ortho Clinical Diagnostics, Tokyo, Japan).15 To determine intracellular HCV core Ag, the cell pellet was resuspended with 100 μL radioimmune precipitation assay buffer containing 1% sodium dodecyl sulfate, 0.5% NP40, 10 mM Tris-HCl (pH 7.4), 1 mM ethylenediaminetetra-acetic acid, 150 mM NaCl, and Complete Mini protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN), then sonicated 10 minutes and subjected to the Ortho HCV core antigen enzyme-linked immunosorbent assay after centrifugation.
Titration of HCV Infectivity.
To assess the intracellular infectivity, cells were harvested by treatment with trypsin-ethylenediaminetetra-acetic acid and pelleted by centrifugation. Cell pellets were resuspended with 500 μL Dulbecco's modified Eagle's medium with 10% fetal bovine serum and lysed by four freeze–thaw cycles. The supernatant was collected after centrifugation and passage through a 0.45-μm filter. These cell lysates and culture supernatants were serially diluted fivefold and inoculated into naïve Huh7.5.1 cells seeded at 1 × 104 cells/well in 96-well flat-bottom plates and assayed for focus-forming unit (FFU) by anti-core immunofluorescence as described previously.16
Data from repeated experiments were averaged and expressed as mean ± standard deviation. Statistical analysis was performed using the Mann-Whitney test. P values of less than 0.05 were considered statistically significant.
Clinical, Virological, and Immunological Profiles of JFH-1–Infected Chimpanzees.
Chimpanzee 10273 (CH10273) was inoculated with patient serum containing 9.6 × 106 copies of HCV RNA. Chimpanzee 10274 (CH10274) was inoculated with 1.4 × 107 copies of JFH-1cc in culture medium. In both chimpanzees, HCV RNA became detectable in serum by RT-PCR 3 days after inoculation. Viremia was low, with titers of approximately 103 copies/mL. Serum ALT levels were within normal limits, and histological observation of liver biopsy showed no evidence of hepatitis (Fig. 1). In CH10273, HCV RNA in serum fluctuated but persisted for 34 weeks after inoculation, and anti-HCV was detected from 20 weeks after inoculation (Fig. 1A). In CH10274, serum HCV RNA disappeared at 9 weeks after inoculation, and no anti-HCV seroconversion was observed (Fig. 1B).
Immunological analysis for T-cell proliferation and IFN-γ production showed that HCV-specific immune responses were induced in both animals (Fig. 1). Their responses corresponded to the profiles of viremia and remained at low levels after disappearance of viremia. The T-cell proliferative responses against the HCV core and NS5a proteins became positive 4 weeks after inoculation and continued up to 30 and 18 weeks in CH10273 and CH10274, respectively. Likewise, the IFN-γ responses against HCV structural and nonstructural antigens were detected 4 weeks after inoculation and maintained 34 weeks and 16 weeks in CH10273 and CH10274, respectively (Fig. 1).
HCV Sequence Analysis.
To investigate the difference and evolution of infected viruses, HCV sequences in both chimpanzees were determined directly at multiple time points as indicated in Fig. 1. In CH10273, HCV sequences were determined with sera collected at weeks 2, 19, and 23. Nineteen synonymous and six nonsynonymous mutations were already observed at week 2, and the number of mutations increased gradually with time (Table 1). Conversely, CH10274 showed no mutation at the earliest time point of infection (week 2) but subsequently developed four synonymous and seven nonsynonymous mutations at week 7 (Table 1). The mutated amino acids in the JFH-1 genome were distributed in E2, NS2, NS5a, and NS5b regions (Fig. 2A). Among these mutations, only one mutation, G838R in NS2, was identified as a common mutation between the two chimpanzees. To assess the complexity of the quasispecies, the amplified fragment encompassing HVR-1 was cloned and 10 clones in each time point were sequenced. In both animals, HVR populations of isolated HCV indicated similarly low complexity of heterogeneity (Fig. 2B). HCV clones isolated from CH10273 contained one HVR-1 mutation N397S at the earliest time point of infection, and this mutation could not be found in clones of the inoculum (Fig. 2B). To exclude the possibility of PCR artifact, sequences were confirmed by independent analyses. To ensure that the common NS2 mutant was not present as a minor species at the earliest time point of CH10274 (week 2), cloning (15 clones) and sequencing was performed and showed the WT sequence.
|Synonymous Mutations*||Non-synonymous Mutationsa||Total|
|#1 (week 2)||19||6||25|
|#2 (week 19)||33||15||48|
|#3 (week 23)||35||17||52|
|#1 (week 2)||0||0||0|
|#2 (week 7)||4||7||11|
Effect of the NS2 Mutation on HCV Life Cycle.
To assess whether this NS2 mutation could be a result of cytotoxic T-lymphocyte escape, which has been described in acutely HCV-infected chimpanzees,17 we tested the T cell response of PBMCs from various time points during the infection against 18-mer peptides encompassing this region (both the WT and mutant sequences were tested). No T cell response could be detected against either the WT or mutant peptides throughout the infection, therefore making cytotoxic T-lymphocyte escape mutation highly unlikely. To assess the phenotype of the observed common mutation, G838R in the NS2 region, JFH-1 construct with this mutation was generated (JFH-1 G838R). Viral replication and production of the JFH-1 G838R mutant was compared with that of the WT JFH-1 (JFH-1 WT) by transfecting the in vitro transcribed full-length genome RNA into Huh7.5.1 cells. HCV RNA levels in culture media of JFH-1 WT and JFH-1 G838R transfected cells were 2.96 × 106 ± 1.63 × 105 and 1.69 × 107 ± 3.61 × 105 copies/mL on day 3, and 2.67 × 106 ± 3.69 × 105 and 1.14 × 107 ± 2.23 × 105 copies/mL on day 5, respectively (P < 0.05)(Fig. 3A). In JFH-1 WT and JFH-1 G838R transfected cells, intracellular HCV RNA levels were 1.14 × 108 ± 1.36 × 107 and 3.66 × 108 ± 1.20 × 107 copies/well on day 3, and 1.67 × 108 ± 3.94 × 107 and 2.23 × 108 ± 1.90 × 107 copies/well on day 5, respectively (P < 0.05) (Fig. 3A). Thus, JFH-1 G838R could produce HCV RNA approximately fivefold higher than the JFH-1 WT in culture media and transfected cells (days 3 and 5, P < 0.05).
To confirm this observation, an infection study was also conducted with cell culture–generated viruses. After transfection of JFH1 WT and JFH-1 G838R genome RNA, viruses in culture media were harvested, and FFU of these viruses were titrated. The same titer of JFH1 WT or JFH-1 G838R viruses was inoculated into naïve Huh7.5.1 cells (9 × 102 FFU, multiplicity of infection = 0.003). After infection, HCV RNA titer in culture medium and infected cells was determined. Consistent with the transfection study, HCV RNA levels in culture media of JFH-1 G838R virus–infected cells were threefold to sixfold higher than those of JFH-1 WT virus (days 3 and 5, P < 0.05; Fig. 3B). Intracellular HCV RNA level on day 5 also appeared to be higher (fivefold) in JFH-1 G838R–infected cells (P < 0.05). Based on these data, JFH-1 G838R replicates more efficiently than the WT.
To further investigate the mechanism of this enhanced replication, we reasoned that this mutation could affect any of the viral RNA synthesis, assembly, or secretion steps. To distinguish among these possibilities, we used Huh7-25 cells, a Huh7 cells–derived cell line lacking CD81 expression.11 This cell line cannot be reinfected by HCV but can support and produce infectious HCV on transfection with the HCV genome, therefore allowing us to address this question without the confounding effect of reinfection. HCV RNA levels of JFH-1 G838R–transfected cells in culture media were eightfold higher on day 1 and threefold higher on day 3 compared with those of JFH-1 WT transfected cells (Fig. 4A, P < 0.05). On day 5, the HCV RNA level was still higher in JFH-1 G838R–transfected cells, but the difference was less. The HCV RNA levels of the replication-deficient clone, JFH-1 GND, transfected cells were substantially lower than both NS2 mutant-transfected and WT-transfected cells (Fig. 4A). Similarly, HCV core Ag in culture media showed a significant difference between JFH-1 WT–transfected and JFH-1 G838R–transfected cells (days 1, 3, and 5, P < 0.05)(Fig. 4B). HCV core Ag of JFH-1 GND–transfected cells was under the detection limit. In contrast to culture media data, intracellular HCV RNA and core Ag levels in JFH-1 G838R–transfected cells were similar to or slightly lower than those of JFH-1 WT–transfected cells. Therefore, the G838R mutation does not appear to affect RNA replication and probably enhances either the assembly or secretion step.
To distinguish between these two possible effects, we determined the infectivity titer of intracellular viral particles in transfected cells as reported previously.18 On day 3 after transfection, the intracellular infectivity titer in JFH-1 G838R–transfected cells was approximately fourfold higher than that in JFH-1 WT–transfected cells (P < 0.05, Fig. 4C and Table 2). Moreover, specific intracellular infectivity of JFH-1 G838R–transfected cells was approximately eightfold higher than that in JFH-1 WT–transfected cells (P < 0.05, Table 2). Specific infectivity in culture medium was determined as the ratio of infectious virus (FFU) over HCV RNA copies. Specific infectivity of the JFH-1 G838R viruses was not significantly different from that of JFH-1 WT (Table 2). Finally, the rate of secretion was determined by the ratio of extracellular FFU over the intracellular FFU (Table 2), and no difference was observed between JFH-1 WT and G838R-transfected cells. Based on these data, the G838R mutation in JFH-1 enhances the assembly step of HCV.
|Clone||Intracellular HCV RNA (copies/well)||Intracellular Intectivity* (FFU/well)||Specific Intracellular Infectivity* (FFU/copies)||Extracellular HCV RNA* (copies/well)||Extracellular Infectivity* (FFU/well)||Specific Exracellular Infectivity (FFU/copies)||Infectious Virus Secretion (extra/intra)|
|JFH-1 WT||4.40 × 107 ± 1.58 × 107||2.27 × 102 ± 5.17 × 101||1.09 × 10−5 ± 2.58 × 10−6||1.83 × 107 ± 1.95 × 106||6.17 × 103 ± 9.61 × 102||3.37 × 10−4 ± 1.38 × 10−3||7.20 ± 2.83|
|JFH-1 G838R||2.19 × 107 ± 1.11 × 106||9.89 × 102 ± 5.02 × 101||9.05 × 10−5 ± 2.76 × 10−6||5.14 × 107 ± 3.48 × 106||2.69 × 104 ± 6.96 × 103||5.33 × 10−4 ± 1.83 × 10−4||6.87 ± 2.07|
Although HCV-associated fulminant hepatitis is rare, several cases have been reported.6, 19–25 The HCV JFH-1 strain was isolated from one of these cases, and its unique characteristic of robust replication in cell culture might be related to the cause of fulminant hepatitis. Previously, HCV from a patient with fulminant liver failure has been shown to cause severe acute hepatitis with high viremia in a chimpanzee, although its molecular clone could not replicate in culture cells and did not induce severe hepatitis in the chimpanzee.26, 27 In our previous study, JFH-1cc induced a transient and attenuated infection in a chimpanzee.8 The infection profile was different from the typical course of HCV infection either with patient sera or infectious RNA molecules in chimpanzees.28–32 Because this observation was unexpected, we reasoned that the lower virulence of this strain in vivo might be related to the age of the chimpanzee. The chimpanzee used in the previous study was older (>25 years of age), and older chimpanzees typically do not develop significant disease on HCV infection. Another possible cause was the characteristics of the viral inoculum. JFH-1cc inoculated in the chimpanzee was monotypic because it was generated in culture cells. The original JFH-1 virus replicating in the fulminant hepatitis patient existed as a mixture of various viral species and might induce a different outcome in vivo. Thus, to elucidate the pathogenesis and replication capacity of the original JFH-1 strain in vivo, the patient serum and the JFH-1cc were inoculated into juvenile chimpanzees (5 years old). However, both chimpanzees showed attenuated infection with low-titer viremia, no ALT elevation, and absence of histological hepatitis during the acute phase of infection. Therefore, the manifestation of fulminant hepatitis of the original patient was likely a result of host factors, with the caveat that humans and chimpanzees might respond differently to HCV infection.
Similar to our previous study, the chimpanzee inoculated with monotypic JFH-1cc showed a short duration of infection and absence of seroconversion. Conversely, the chimpanzee inoculated with the patient serum showed a longer course of infection and developed anti-HCV antibodies. Immunological analysis with T-cell proliferation and IFN-γ ELISpot assays showed that HCV-specific immune responses were similarly induced in both animals and abated with the disappearance of viremia. Consistent with the longer viremia, the chimpanzee inoculated with the patient serum had a longer duration of detectable HCV immune response (Fig. 1). These differences could be explained by the sequence variations of the infecting HCV. In the chimpanzee inoculated with the patient serum, the infecting HCV showed a low sequence complexity but exhibited some sequence diversity already at week 2. The infecting HCV had a sequence alteration in the HVR-1 (N397S), but this sequence alteration could not be found in any of the 20 clones of the inoculum (Fig. 2B).6 In addition, the NS2 G838R mutation was also not detected by cloning (six clones) and sequencing of the inoculum. Thus, this infecting HCV was probably selected from a minor species in the patient serum. It has been reported that minor clones in human serum were selected during HCV infection in chimpanzees.33 The selected clones were in the lighter fraction of the sucrose density gradient of the inoculum, which is devoid of immunoglobulins. Similar selection might have occurred in our study. The dominant clones in the inoculum might not be infectious because of binding to neutralizing antibodies. As a result, the infection-competent minor clone, selected during the infection, became the dominant species. Furthermore, this infecting minor clone could persist longer, although the characteristics of this clone and mechanisms for persistence are still unknown. HCV clones in CH10273 showed several other mutations at 2 weeks postinfection and accumulated additional mutations in E2, NS2, NS3, NS4b, NS5a, and NS5b regions over time (Fig. 2). Some of these regions contain known T-cell epitopes, although the major histocompatibility complex haplotype of this animal is unknown. In this chimpanzee, heterogeneity of the inoculating viruses might have contributed to the emergence of escape mutants from the host immune system, resulting in a prolonged infection. Similar observations have been reported in acute HCV infection in chimpanzees and humans.34–36
In HCV strains isolated from these two chimpanzees, one common mutation G838R in the NS2 region was identified. This mutation has not been reported among the adaptive mutations emerged in the JFH-1 virus passaged in cell culture.37–39 This mutation likely arose de novo because one of the chimpanzees was inoculated with a molecular clone, and the week 2 sample did not harbor this mutation. NS2 is a membrane-associated cysteine protease, composed of three transmembrane domains and a protease domain.40 Although the NS2 region is dispensable for RNA replication, it is essential for production of infectious virus in cultured cells.41–43 Furthermore, the significance of this region has been shown in the establishment of replication-competent and infection-competent intergenotypical chimeric viruses.44, 45 The identified common mutation G838R was at the end of the first transmembrane domain,46 and mutations in the transmembrane domains have been shown to improve the yield of infectious virus production in several studies.45, 47 Thus, some advantage of this mutation in HCV replication and production could be expected. This mutation was shown to enhance HCV production in Huh7.5.1 cells. Detailed analysis with CD81-negative Huh7-25 cell demonstrated that viral assembly was affected by this mutation. Production of infectious virus in JFH-1 G838R–transfected cells was eightfold higher than that in the JFH-1 WT–transfected cells. Thus, this mutation enhances the assembly of infectious virus particle in cultured cells, and as a result, increases infectious virus production in the culture medium. This mutation represents the first identified in vivo adapted mutation that is not immunologically mediated and probably confers a replication advantage to the virus in vivo. This adaptive mutation, unlike the other adaptive mutations reported in vitro with poor infectivity in vivo, likely results from a highly biologically relevant event in the dynamic interaction between HCV and host. Finally, it is possible that compensatory mutations in other regions of the virus may contribute to the overall biological adaptive response of the virus in vivo.
This study demonstrates that the HCV JFH-1 strain either generated in cell culture as a monotypic virus or obtained from patient serum is associated with attenuated infection in chimpanzees; however, the virus can rapidly evolve with adaptive mutations to facilitate propagation of the virus in a susceptible host.
The authors thank Charles Rice and Francis Chisari for providing the cell lines and the veterinary staff for technical assistance in the chimpanzee experiment.